Zoetis Reports Divestiture of its Medicated Feed Additive Portfolio to Phibro Animal Health
Shots:
- Zoetis has signed a definitive agreement with Phibro Animal Health under which Phibro will acquire the company’s medicated feed additive (MFA) product portfolio, some water-soluble products & related assets for an aggregate of $350M. The transaction is anticipated to conclude in H2’24
- The acquisition covers >37 product lines from the portfolio along with 6 manufacturing sites incl. 4 in the US and 1 in Italy & China
- Through this divestment, Zoetis will be able to utilize its livestock investments for developing other solutions such as vaccine, biologic & genetic programs
Ref: Zoetis | Image: Zoetis
Related News:- Zoetis’ Librela (bedinvetmab) Receives the US FDA’s Approval to Control Osteoarthritis Pain in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
